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and 31/03/2010, were identified through examination of electronic patient records.
Exclusion criteria included patients with atrial flutter (AFl), or an ICD10 code indi-
cating prior inpatient attendance for AF since 1995. Patient notes were reviewed
manually and an anonymised data collection template completed by the clinician
for analysis. RESULTS: Of the 126 patients meeting the inclusion criteria, the notes
of 7 patients were unobtainable and 8 with a diagnosis of AFl were excluded. The
majority of patients were symptomatic at presentation (56%) and less than half
were male (41%). Within the study population, the frequency of patients with AF
increased with age, peaking at 80-89 years (45% of the study sample). Method of
admission was primarily through A&E or GP referral (48% each); with 50% of A&E
admissions being for symptomatic AF, compared with 60% of those referred via a
GP. Almost half the study population were recorded with “first detected AF” (47%);
67% of whom were symptomatic, compared to 47% being symptomatic in patients
recorded as “not first detected AF”. The majority of patients were reported to have
1 or 2 of the pre-defined co-morbidities of interest (29% each); one fifth had no
co-morbidities. The most common co-morbidities were hypertension (51%), isch-
aemic heart disease (20%), heart failure (18%), diabetes (16%) and pulmonary dis-
ease (15%). CONCLUSIONS: Results from this study demonstrate the majority of
patients presenting to secondary care with AF have multiple associated co-mor-
bidities, which are known to influence the management and treatment strategy,
and long-term complications. Further up-to-date epidemiological studies, which
describe the history, management and prognosis of patients with AF, are required.
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OBJECTIVES: To analyze the add-on and switch patterns for patients who dis-
pensed platelet aggregation inhibitors, excluding heparin (acetylsalicylic acid,
clopidogrel, and dipyridamole) in the South-West region of Sweden. METHODS:
This was a retrospective database study of medication utilization amongst patients
from the South-West region of Sweden (1.5 million inhabitants). All patients who
dispensed platelet aggregation inhibitors (B01AC), excluding heparin, from 2006 to
2009 were included in the study. A dispatch was classified as new, switch, add-on,
or continuation. All dispatches were annotated, at the ATC level, as either new (no
other anticoagulant within 105 days), add-on (another anticoagulant dispatched
both before and after), switch (another anticoagulant dispatched before, but not
after), or continuation (dispatched same ATC-code within 105 days). RESULTS: 163
330 patients had at least one B01AC filled prescription. The total number of dis-
patches for these patients were 3 327 499. 96% of all patients had been dispatched
acetylsalicylic acid (ASA), 11% clopidogrel and 6% dipyridamole. ASA was dis-
patched as a new prescription in 17% of all dispatches, in 0.5% as add-on, 0.5%
as switch, and in 83% as continuation. For clopidogrel the distribution was 17%
(new), 4% (add-on), 3% (switch), and 77% (continuation). For dipyridamole the dis-
tribution was 7%, 18%, 8%, and 68%. CONCLUSIONS: Not surprisingly ASA was by
far the most common treatment. ASA and Clopidogrel both had first line treatment
profiles, of which it was most pronounced for ASA (1% add-on or switch). Dipyr-
idamole is used more as an add-on or switch therapy with 18% as add-on, 8% as
switch, and only 7% as new dispatches.
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OBJECTIVES: To describe the frequency of adverse drugs events (ADEs) as possible
causes of request of drugs not included in essential Medicines list in Colombia
METHODS: This was a retrospective, descriptive study developed in a private med-
ical insurance company in Bogota, Colombia. Data were obtained from drug re-
quest form of drugs not included in a national essential Medicines list. We analyzed
the content of the notes to identify the records related to the occurrence of ADEs in
the period 2005 to 2008. Information concerning the adverse event and the drug
involved was recorded in a data collection instrument developed by the research-
ers. The pharmacological classification of drugs was performed according to the
Anatomical Therapeutic Chemical Classification System (ATC). Univariate descrip-
tive statistical analysis was performed RESULTS: A total of 116 cases of ADEs were
detected. The level 1 groups of the ATC of drugs with greater frequency of ADEs
were the cardiovascular agents (66; 47.15%), nervous system agents (34; 23.7 %) and
antineoplastic and immunomodulating agents (21; 14.7 %). The great majority was
cases of light severity (89; 62.7 %) and classified as possible (66; 48.4 %).
CONCLUSIONS:We conclude that our study encourages the private medical insur-
ance companies in developing countries to design pharmacosurveillance pro-
grams; recognizing the importance of looking for new sources of report of adverse
reactions to diminish the under-notification of ADEs.
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OBJECTIVES: Hypertension is a leading global risk factor for the burden of cardio-
vascular disease. Data about changes in hypertension control are important to set
intervention priorities. We conducted a systematic review and meta-analysis of
epidemiological studies to determine the control of hypertension in Spain over the
last decade. METHODS: A search of PubMed/MEDLINE, SCOPUS and IME was per-
formed for epidemiological studies conducted in Spain (since 2000) with data on
control rates for hypertension. The primary outcome was the prevalence of uncon-
trolled hypertension defined as the percentage of patients having systolic blood
pressure (SBP)  140 mmHg and/or diastolic blood pressure (DBP)  90 mmHg. For
populations at risk (e.g. patients with diabetes), the definition was SBP 130 mmHg
and/or DBP  80-85 mmHg. Pooled-prevalence estimates and 95% confidence in-
tervals (95% CI) were determined by random-effects models using the inverse vari-
ance method. Heterogeneity was assessed using Cochran’s Q and I2 statistics.
RESULTS: Seventy-six studies evaluating 341,632 patients (79% with hypertension)
met the inclusion criteria. Among hypertensive patients, the overall pooled-prev-
alence of uncontrolled hypertension ( 140/90 mmHg) was 67.0% (95% CI: 64.1% to
69.9%), but was 87.6% (95% CI: 86.2 to 89.0%) when the most restricted definition (
130/80-85 mmHg) was used for patients at risk. The test for heterogeneity was
significant (P0.001). Using metaregression analyses, we showed that the preva-
lence of uncontrolled hypertension did not change significantly over time, but the
percentage of patients receiving at least two antihypertensive drugs increased
(P0.032, and 0.001). CONCLUSIONS: In Spain, the control of hypertension is far
from optimum and does not appear to have improved in recent years despite the
increased intensity of therapy. Patients at risk with comorbidities appear to be
controlled worse.
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OBJECTIVES: Recent in-hospital mortality data among heart failure (HF) patients in
the The Netherlands are lacking. This study described in-hospital mortality rates
among HF patients in the The Netherlands from 2005 to 2009. METHODS: The
PHARMO database network includes, among other things, hospitalization records
of approximately 3.2 million residents in the The Netherlands. From this database,
all patients with a hospitalization for HF between 2005 and 2008 were selected. The
date of the first HF admission was defined as the index date. Patients hospitalized
for HF in the 12 months prior to index date were excluded. Patients were followed
from index date until end of data collection, death, or a maximum of 12 months,
whichever occurred first. Crude mortality rates over time were determined during
index HF admission, any HF readmission, and during any all-cause readmission .
RESULTS: The study included 9786 patients with an index HF admission. Mean (
SD) age was 77 ( 11) years and 52% were female. During index HF admission (mean
(SD) length of stay (LOS):11 (10) days) 10% of patients died. Hence, 8,850 patients
were at risk for readmission. During follow-up, 1,563 (18%) patients were readmit-
ted for HF and 4,542 (51%) patients had an all-cause readmission. In-hospital mor-
tality during HF readmission (mean (SD) LOS: 11 (9) days) was also 10%. In-
hospital mortality during all-cause readmission (mean (SD) LOS: 7 (11) days),
was 5%. Mortality rates over time from 2005 to 2009 were stable. Mean (SD) num-
ber of days between hospital (re)admission and death was 10 (13) days for the
index HF admission and 12 (12) days for both HF readmission and all-cause read-
mission (12 (15) days). CONCLUSIONS: In most recent years, in-hospital mortality
remains unchanged with 10% of HF patients dying during HF admission.
PCV30
HEART FAILURE (RE)ADMISSIONS IN THE NETHERLANDS: RATES, LENGTH OF
STAY AND COSTS
Overbeek JA1, Penning-van Beest FJA1, Herings RMC2, Agodoa I3
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Erasmus Medical
Centre, Rotterdam, The Netherlands, 3Amgen Inc., Thousand Oaks, CA, USA
OBJECTIVES: Hospital admissions are common among heart failure (HF) patients
and contribute to the significant clinical and economic burden of HF. This study
determined rates, length of stay (LOS) and costs of HF (re)admissions. METHODS:
The PHARMO database network includes, among other things, hospitalization re-
cords of approximately 3.2 million residents in the The Netherlands. From this
database, all patients with a primary hospital discharge code for HF between 2005
and 2008 were selected. Date of first HF admission was defined as index date.
Patients hospitalized for HF in the 12 months prior to index date were excluded.
Patients were followed from index date to end of data collection, death, or a max-
imum of 12 months, whichever occurred first, in order to assess primary hospital-
izations for HF within one year, i.e. HF readmissions . Main outcomes for each
identified HF (re)admission were LOS (in days) and costs per (re)admission (amount
paid in €). RESULTS:The study included 9,786 patients with an index HF admission.
Mean ( SD) age was 77 ( 11) years and 52% were female. Mean ( SD) LOS was 11
 10 days and mean ( SD) hospitalization costs of index HF admission were €8,650
( €9,100). During the index HF admission 936 patients died, therefore 8,850 pa-
tients were at risk for a HF readmission. Of those patients, 1,563 patients were
readmitted for HF within one year. Overall, one-year HF readmission rate was 21.8
per 100 person years. Mean ( SD) LOS of first HF readmission was 10 10 days and
mean ( SD) hospitalization costs of first HF readmission were €8,850 ( €8,450).
CONCLUSIONS: One fifth of patients hospitalized for HF in the The Netherlands
have a subsequent HF admission within one year. Overall, costs of index HF admis-
sion and first HF readmission are similar.
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